An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.
G. D. Demetri
Consultant or Advisory Role - GlaxoSmithKline; Infinity; Kolltan Pharmaceuticals; Novartis; Pfizer; Roche/Genentech
Stock Ownership - Kolltan Pharmaceuticals
Research Funding - Synta
M. C. Heinrich
Research Funding - Synta
B. Chmielowski
No relevant relationships to disclose
J. A. Morgan
No relevant relationships to disclose
S. George
No relevant relationships to disclose
R. Bradley
Employment or Leadership Position - Synta
Stock Ownership - Synta
R. K. Blackman
Employment or Leadership Position - Synta
Stock Ownership - Synta
F. Teofilovici
Employment or Leadership Position - Synta
Stock Ownership - Synta
J. A. Fletcher
Research Funding - Synta
W. D. Tap
No relevant relationships to disclose
M. von Mehren
Research Funding - Synta